Transcriptomics

Dataset Information

0

Phase Ib/II Study of Azacitidine, Venetoclax and Magrolimab in Adult Patients with Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia

ABSTRACT: To better understand the mechanisms of response and resistance to azacitdine, venetoclax, and magrolimab (AVM), we performed single-cell RNA-sequencing (scRNAseq) on 27 samples (11 pre- and 16 post-treatment) from 11 TP53-mutated patients with combined therapy

ORGANISM(S): Homo sapiens

PROVIDER: GSE269669 | GEO | 2025/03/28

REPOSITORIES: GEO

Json Xml

Similar Datasets

Unknown Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
| S-EPMC9028084 | biostudies-literature
Genomics Phase Ib/II Study of Azacitidine, Venetoclax and Magrolimab in Adult Patients with Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia
| PRJNA1123202 | ENA
Unknown Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
| S-EPMC9508061 | biostudies-literature
Unknown Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
| S-EPMC10149010 | biostudies-literature
Unknown Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
| S-EPMC8714726 | biostudies-literature
Unknown A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia.
| S-EPMC10046472 | biostudies-literature
Unknown A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
| S-EPMC10100228 | biostudies-literature
Unknown Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.
| S-EPMC7951133 | biostudies-literature
Unknown Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
| S-EPMC6158762 | biostudies-literature
Unknown 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
| S-EPMC7549397 | biostudies-literature